Luke Nelson and Kyleen Castro co-author New ccRCC Paper

Doctorial students, Luke Nelson and Kyleen Castro co-authored a new paper published in Cell Cycle describing the synthetic lethality of CDK inhibitor Dinaciclib on VHL-Deficient clear cell Renal Cell Carcinomas. Nelson, L.J., Castro, K.E., Xu, B., Li, J., Dinh, N.B., Thompson, J.M., Woytash, J., Kipp, K.R. & Razorenova, O.V. Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma. Cell Cycle, 1-17 (2022).